# PT-141: Clinical Guide for Practices > PT-141 (Bremelanotide) is a melanocortin receptor agonist that acts centrally to enhance sexual desire and arousal. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. In compounding, it is prescribed for both male and female sexual dysfunction. **FDA compounding category:** FDA-approved as Vyleesi for HSDD; compounded versions available for broader off-label use **Category:** Sexual Health **Route of administration:** Subcutaneous injection, intranasal ## Mechanism of action PT-141 is a cyclic heptapeptide that activates melanocortin-4 receptors (MC4R) in the medial preoptic area and paraventricular nucleus of the hypothalamus, triggering downstream dopaminergic and oxytocinergic pathways involved in sexual arousal [3]. Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, PT-141 modulates central nervous system circuits governing desire and motivation [2]. It also demonstrates partial agonist activity at MC3R, contributing to its effects on both arousal and appetite regulation [4]. ## Evidence summary The RECONNECT Phase III trials (two pivotal studies, n=1247) demonstrated statistically significant increases in satisfying sexual events and desire scores versus placebo in premenopausal women with HSDD, leading to FDA approval as Vyleesi in June 2019 [1][2]. Phase II studies in men with erectile dysfunction showed improved erection quality in approximately 70% of subjects, including those unresponsive to sildenafil [4]. Clinical pharmacology data confirm peak onset at 45 to 60 minutes post-injection with duration of action of 12 to 24 hours [3]. The melanocortin mechanism represents the first centrally acting pharmacotherapy approved specifically for female sexual desire [1]. ## Patient selection FDA-approved for premenopausal women with acquired, generalized HSDD not explained by relationship, medical, or psychiatric factors [1][2]. Off-label candidates include men with erectile dysfunction refractory to PDE5 inhibitors (particularly those with desire-based dysfunction) [4], postmenopausal women with HSDD, and patients on SSRI/SNRI medications with treatment-emergent sexual dysfunction [3]. Contraindicated in patients with uncontrolled hypertension or cardiovascular disease. Screen for concurrent naltrexone use, which may reduce efficacy. ## Clinical uses - Hypoactive sexual desire disorder (HSDD) in women (FDA-approved indication) - Erectile dysfunction unresponsive to PDE5 inhibitors - Male sexual dysfunction - Libido enhancement in both sexes ## Protocols and dosing Administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity. FDA-approved dose is 1.75mg as needed, not to exceed one dose per 24 hours or 8 doses per month. FDA-approved dose (Vyleesi) is 1.75 mg subcutaneous, administered at least 45 minutes before anticipated sexual activity [1]. Maximum frequency is one dose per 24 hours and no more than 8 doses per month [2]. For patients experiencing significant nausea, initiating at 1.0 mg and titrating to 1.75 mg over 2 to 3 uses improves tolerability. Compounded formulations for male patients are typically dosed at 1.5 to 2.0 mg subcutaneous [4]. Intranasal formulations (historical) were dosed at 10 to 20 mg but are no longer preferred due to variable absorption and higher nausea rates [3]. ## Side effects to monitor - Nausea (40% incidence; most common and potentially dose-limiting) - Flushing and facial warmth (25% incidence) - Headache (mild to moderate, typically resolves within hours) - Transient blood pressure elevation (average 6-8 mmHg systolic) - Injection site reactions (erythema, pruritus) ## Clinical considerations FDA-approved (Vyleesi) for HSDD in premenopausal women,Common side effects include nausea, flushing, and headache; nausea may be dose-limiting,Can cause transient blood pressure elevation; screen for uncontrolled hypertension,Not recommended for use with naltrexone (may reduce efficacy),Limit to 8 doses per month per FDA labeling ## Practice economics Sexual health is a high-demand, cash-pay category with strong patient willingness to pay out-of-pocket. PT-141's FDA-approved status (Vyleesi) provides regulatory credibility and reduces liability concerns compared to unapproved peptides [1]. Practices can offer full sexual wellness programs combining PT-141 with hormone optimization, generating recurring revenue from an underserved and growing patient demographic [2]. ## Frequently asked questions ### How does PT-141 differ from PDE5 inhibitors like sildenafil? PT-141 works centrally through melanocortin receptors in the brain to enhance sexual desire and arousal, while PDE5 inhibitors (sildenafil, tadalafil) work peripherally on blood flow to the genitals. PT-141 addresses desire and arousal at the neurological level, making it useful for patients who don't respond to PDE5 inhibitors or whose dysfunction is desire-based rather than vascular. ### Can PT-141 be prescribed for men? Yes. While the FDA approval (Vyleesi) is specifically for HSDD in premenopausal women, compounded PT-141 is widely prescribed off-label for male sexual dysfunction, particularly erectile dysfunction that is unresponsive to PDE5 inhibitors. Clinical justification and informed consent are required for off-label use. ### What is the nausea management strategy for PT-141? Nausea is the most common side effect and can be dose-limiting. Strategies include starting at lower doses (1mg vs 1.75mg), taking with food, using anti-emetics prophylactically, and subcutaneous rather than intranasal administration. Most patients develop tolerance to nausea with repeated use. ## Sources - [FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. FDA News Release, June 21, 2019.](https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hypoactive-sexual-desire-disorder-premenopausal-women) - [Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.](https://pubmed.ncbi.nlm.nih.gov/31599840/) - [Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-38.](https://pubmed.ncbi.nlm.nih.gov/16839319/) - [Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med. 2008;5(5):1088-96.](https://pubmed.ncbi.nlm.nih.gov/18331256/) --- Canonical page: https://karpahealth.com/resources/peptides/pt-141/ Markdown version of the HTML page "pt-141" at that URL. Machine-readable context: https://karpahealth.com/llms.txt · Pricing: https://karpahealth.com/pricing.md · Agents & API: https://karpahealth.com/agents.md